The Key Laboratory for Cardiovascular Antibodies and Large Molecule Innovative Drugs, led by Rejing Biotechnology, has been officially approved.

According to the latest news from Rejing Biotech, the key technologies and industrialization of cardiovascular antibodies and innovative macromolecular drugs have been officially recognized by the Beijing Municipal Science and Technology Commission and the Zhongguancun Management Committee as a key laboratory in Beijing. The laboratory is led by Beijing Rejing Biotechnology Co., Ltd., and jointly established with Beijing Shunjing Biomedical Technology Co., Ltd., Beijing Institute of Cardiovascular and Pulmonary Vascular Diseases, and Beijing Yaojing Gene Technology Co., Ltd. It is an important platform for the layout of cardiovascular frontier innovation in the field of medicine and health in the capital, and for carrying out core technical breakthroughs.